DYAI - Pangali EV/EBITDA Dyadic International, Inc.

The growth of Dyadic International (DYAI) is driven by the implementation of the C1 system for budget protein synthesis and vaccination, as well as licensing payments. This daily price chart confirms the trend, where the EV/EBITDA ratio stands at 0.00. The business relies on partnership contracts for drug development. Efficiency is increasing through the deployment of autonomous stations, which completely eliminate manual labor during the selection of antiviral drugs.

Scaling the C1 platform for protein expression directly impacts the operational efficiency of Dyadic International (DYAI) and its ability to generate licensing revenue. An analysis of the current EV/EBITDA with debt allows for a business valuation that accounts for credit load and taxes, helping investors determine the fair value of assets and avoid value traps while searching for a local market bottom.